Rheumatoid Arthritis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Rheumatoid Arthritis - Pipeline Review, H1 2016

Rheumatoid Arthritis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Rheumatoid Arthritis - Pipeline Review, H1 2016
Published Jun 28, 2016
1143 pages — Published Jun 28, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Rheumatoid Arthritis - Pipeline Review, H1 2016, provides an overview of the Rheumatoid Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis
- The report reviews pipeline therapeutics for Rheumatoid Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Rheumatoid Arthritis therapeutics and enlists all their major and minor projects
- The report assesses Rheumatoid Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline

  
Source:
Document ID
GMDHC7957IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents259
  List of Tables528
  List of Figures601
Introduction611
  Global Markets Direct Report Coverage611
Rheumatoid Arthritis Overview621
Therapeutics Development632
  Pipeline Products for Rheumatoid Arthritis Overview631
  Pipeline Products for Rheumatoid Arthritis Comparative Analysis641
Rheumatoid Arthritis Therapeutics under Development by Companies6518
Rheumatoid Arthritis Therapeutics under Investigation by Universities/Institutes833
Rheumatoid Arthritis Pipeline Products Glance864
  Late Stage Products861
  Clinical Stage Products871
  Early Stage Products881
  Unknown Stage Products891
Rheumatoid Arthritis Products under Development by Companies9028
Rheumatoid Arthritis Products under Investigation by Universities/Institutes1183
Rheumatoid Arthritis Companies Involved in Therapeutics Development121222
  3SBio Inc.1211
  4D Pharma Plc1221
  4SC AG1231
  AB Science SA1241
  AB2 Bio Ltd.1251
  AbbVie Inc.1261
  Ablynx NV1271
  ACEA Biosciences, Inc.1281
  Addex Therapeutics Ltd1291
  Advinus Therapeutics Ltd1301
  AlphaMab Co., Ltd1311
  Alteogen Inc.1321
  Amgen Inc.1331
  Amura Holdings Limited1341
  Anacor Pharmaceuticals, Inc.1351
  Applied Genetic Technologies Corporation1361
  ARA Healthcare Pvt. Ltd.1371
  Arena Pharmaceuticals, Inc.1381
  Arrien Pharmaceuticals, LLC1391
  Arthrogen BV1401
  Asahi Kasei Pharma Corp.1411
  Asana BioSciences, LLC1421
  Astellas Pharma Inc.1431
  AstraZeneca Plc1441
  Avexxin AS1451
  Axxam SpA1461
  BCN Peptides, S.A.1471
  Bio-Cancer Treatment International Limited1481
  BIOCAD1491
  Biocon Limited1501
  Biokine Therapeutics Ltd.1511
  BioLingus AG1521
  BioLite, Inc.1531
  Bionovis SA1541
  BioTherapeutics Inc.1551
  Bird Rock Bio, Inc.1561
  Boehringer Ingelheim GmbH1571
  Bone Medical Limited1581
  Boryung Pharmaceutical Co., Ltd.1591
  Bristol-Myers Squibb Company1601
  Can-Fite BioPharma Ltd.1611
  Cardax Pharmaceuticals, Inc.1621
  CASI Pharmaceuticals Inc.1631
  CEL-SCI Corporation1641
  Celgene Corporation1651
  Cellceutix Corporation1661
  Celltrion, Inc.1671
  ChemoCentryx, Inc.1681
  Chipscreen Biosciences Ltd1691
  ChironWells GmbH1701
  Chong Kun Dang Pharmaceutical Corp.1711
  CJ HealthCare Corp.1721
  CLL Pharma1731
  Clonz Biotech Private Limited1741
  Coherus BioSciences, Inc.1751
  Commence Bio, Inc.1761
  Compugen Ltd.1771
  Confluence Life Sciences, Inc.1781
  CSL Limited1791
  Cyclacel Pharmaceuticals, Inc.1801
  Daiichi Sankyo Company, Limited1811
  Diamyd Medical AB1821
  Domainex Limited1831
  Dr. Reddy's Laboratories Limited1841
  Eisai Co., Ltd.1851
  Eli Lilly and Company1861
  Enceladus Pharmaceuticals BV1871
  Endocyte, Inc.1881
  Enzene Biosciences Ltd.1891
  Epirus Biopharmaceuticals, Inc.1901
  F. Hoffmann-La Roche Ltd.1911
  Five Prime Therapeutics, Inc.1921
  Fountain Biopharma Inc.1931
  Galapagos NV1941
  Gene Techno Science Co., Ltd.1951
  Genentech, Inc.1961
  Genor BioPharma Co., Ltd.1971
  Genosco1981
  Gilead Sciences, Inc.1991
  GlaxoSmithKline Plc2001
  Griffin Discoveries BV2011
  Han Wha Pharma Co., Ltd.2021
  Handok Inc.2031
  Hanmi Pharmaceuticals, Co. Ltd.2041
  Hansa Medical AB2051
  Hanwha Chemical Corporation2061
  HEC Pharm Co., Ltd.2071
  Hetero Drugs Limited2081
  HitGen LTD2091
  Huabo Biopharm Co., Ltd.2101
  Hutchison MediPharma Limited2111
  Idera Pharmaceuticals, Inc.2121
  Idogen AB2131
  Immune Response BioPharma, Inc.2141
  Immungenetics AG2151
  ImmunoFrontier, Inc.2161
  Innate Pharma S.A.2171
  Innovent Biologics, Inc.2181
  Intas Pharmaceuticals Ltd.2191
  ISU ABXIS Co.,Ltd.2201
  JHL Biotech, Inc.2211
  Jiangsu Hengrui Medicine Co., Ltd.2221
  Johnson &Johnson2231
  Jyant Technologies, Inc.2241
  Kadmon Corporation, LLC2251
  KAHR medical Ltd.2261
  Kang Stem Biotech Co., Ltd.2271
  Karus Therapeutics Limited2281
  Karyopharm Therapeutics, Inc.2291
  Kezar Life Sciences, Inc.2301
  Kineta, Inc.2311
  Kolltan Pharmaceuticals, Inc.2321
  Lead Pharma Holding B.V.2331
  Lexicon Pharmaceuticals, Inc.2341
  LG Life Science LTD.2351
  Lipocure Ltd.2361
  LSK BioPartners, Inc.2371
  Lupin Limited2381
  Mabion SA2391
  Mabtech Limited2401
  mAbxience S.A.2411
  MacroGenics, Inc.2421
  Mebiopharm Co., Ltd.2431
  MedAnnex Ltd2441
  Medestea Research &Production S.p.A.2451
  MediGene AG2461
  MedImmune, LLC2471
  Mesoblast Limited2481
  Millennium Pharmaceuticals, Inc.2491
  Mitsubishi Tanabe Pharma Corporation2501
  Modern Biosciences Plc2511
  ModiQuest Group2521
  Momenta Pharmaceuticals, Inc.2531
  Morphotek, Inc.2541
  Mycenax Biotech Inc.2551
  MYOS RENS Technology Inc.2561
  Myungmoon pharmaceutical Co., Ltd.2571
  NanoSmart Pharmaceuticals, Inc.2581
  Navigen Pharmaceuticals, Inc.2591
  Neovacs SA2601
  Nimbus Therapeutics, LLC2611
  Nissan Chemical Industries, Ltd.2621
  Novartis AG2631
  NovImmune SA2641
  Nuevolution AB2651
  Omeros Corporation2661
  Oncobiologics, Inc.2671
  Oncodesign SA2681
  OncoImmune, Inc.2691
  Ono Pharmaceutical Co., Ltd.2701
  OPKO Health, Inc.2711
  Opsona Therapeutics Limited2721
  Oscotec Inc.2731
  OSE Immunotherapeutics2741
  Panacea Biotec Limited2751
  Paras Biopharmaceuticals Finland Oy2761
  Parvus Therapeutics, Inc.2771
  Peptinov SAS2781
  Pfenex Inc.2791
  Pfizer Inc.2801
  Pharmacyclics, Inc.2811
  Pharmedartis GmbH2821
  Phenex Pharmaceuticals AG2831
  Philogen S.p.A.2841
  PLx Pharma Inc.2851
  Principia Biopharma Inc.2861
  Progenra, Inc.2871
  ProNoxis AB2881
  ProtAb Ltd2891
  Protagonist Therapeutics Inc.2901
  Protalex, Inc.2911
  Protalix BioTherapeutics, Inc.2921
  Qu Biologics Inc.2931
  R-Pharm2941
  Re-Pharm Limited2951
  ReceptoPharm, Inc.2961
  RedHill Biopharma Ltd.2971
  Redx Pharma Plc2981
  Regeneron Pharmaceuticals, Inc.2991
  Resverlogix Corp.3001
  ReveraGen BioPharma, Inc.3011
  Rhizen Pharmaceuticals S.A.3021
  Richter Gedeon Nyrt.3031
  Saje Pharma, LLC3041
  Sandoz International GmbH3051
  Sareum Holdings Plc3061
  SBI Biotech Co., Ltd.3071
  Selvita S.A.3081
  Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.3091
  Shanghai Henlius Biotech Co., Ltd.3101
  Shanghai Pharmaceutical Co., Ltd.3111
  Swedish Orphan Biovitrum AB3121
  Synovo GmbH3131
  Syntrix Biosystems, Inc.3141
  TaiwanJ Pharmaceuticals Co., Ltd.3151
  Takeda Pharmaceutical Company Limited3161
  TechnoPhage SA3171
  Teijin Pharma Limited3181
  The International Biotechnology Center (IBC) Generium3191
  TheraMAB LLC3201
  Therapeutic Proteins International, LLC3211
  TiGenix NV3221
  Toleranzia AB3231
  Tumorend, LLC3241
  TxCell SA3251
  U.S. Stem Cell, Inc.3261
  UCB S.A.3271
  United BioPharma, Inc.3281
  Vaccinex, Inc.3291
  Valeant Pharmaceuticals International, Inc.3301
  Vichem Chemie Research Ltd.3311
  Vicore Pharma AB3321
  Vida Therapeutics Inc.3331
  Vitae Pharmaceuticals, Inc.3341
  Vitaeris Inc3351
  Xbrane Biopharma AB3361
  Xencor, Inc.3371
  XTL Biopharmaceuticals Ltd.3381
  Yungjin Pharm. Co., Ltd.3391
  Yuyu Pharma, Inc.3401
  Zenyaku Kogyo Co., Ltd.3411
  Zydus Cadila Healthcare Limited3421
Rheumatoid Arthritis Therapeutics Assessment34334
  Assessment by Monotherapy Products3431
  Assessment by Combination Products3441
  Assessment by Target34513
  Assessment by Mechanism of Action35815
  Assessment by Route of Administration3732
  Assessment by Molecule Type3752
Drug Profiles377767
  (clarithromycin + clofazimine + rifabutin) Drug Profile3777

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Rheumatoid Arthritis - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rheumatoid-Arthritis-Pipeline-Review-H1-2016-2088-16017>
  
APA:
Global Markets Direct - Market Research. (2016). Rheumatoid Arthritis - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rheumatoid-Arthritis-Pipeline-Review-H1-2016-2088-16017>
  
US$ 2,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.